Spend $99, get free U.S. shipping*
Tariff now required on U.S. shipments. Learn more »
Tel: 1-866-456-3768 Fax: 1-866-544-8993
For visual reference only; actual product may vary
For visual reference only; actual product may vary
Kisunla (donanemab-azbt) is a prescription intravenous therapy for adults diagnosed with early-stage Alzheimer’s disease. Administered monthly, it targets and clears amyloid beta plaques from the brain to help slow down the progression of cognitive and functional decline. This product requires special cold shipping.
| Kisunla Brand | 350mg 1 Vial |
-
|
Our price: $1,255.00 |
Kisunla is a prescription antibody therapy used to treat adults with early symptomatic Alzheimer’s disease. It is designed for patients who have mild cognitive impairment or are in the mild dementia stage of the illness. The primary goal of Kisunla is to target the underlying pathology of Alzheimer’s by removing harmful protein deposits in the brain. This can help slow the rate of cognitive decline. Treatment is specifically for patients whose brains show the presence of amyloid beta plaques.
Kisunla works by targeting and removing a specific protein called amyloid beta. This protein can clump together in the brain, forming sticky plaques that disrupt communication between brain cells and lead to cell death. Kisunla is a monoclonal antibody, which is a man-made protein that acts like a natural antibody. It binds directly to these established amyloid plaques. By attaching to the plaques, it signals the body’s own immune cells to clear them away, reducing the overall plaque burden in the brain and slowing disease progression.
Kisunla is for adults who are in the early stages of Alzheimer’s disease. This includes individuals experiencing mild cognitive impairment (MCI) or mild dementia where Alzheimer’s is the confirmed cause. Before starting treatment, a doctor must confirm the presence of amyloid beta plaques in the brain, usually through a PET scan or cerebrospinal fluid test. The medication is not intended for people in later stages of the disease or for those without evidence of amyloid plaques. It is for patients seeking to slow the decline in memory and thinking.
Kisunla is administered as an intravenous (IV) infusion by a healthcare professional once every four weeks. Each infusion session typically lasts about 30 to 60 minutes. The dosage is based on the patient’s body weight. The treatment plan is unique because therapy may be stopped if a patient achieves a certain level of amyloid plaque clearance, as determined by brain imaging. Your doctor will monitor your progress and amyloid levels to determine the appropriate duration of treatment. Regular monitoring for side effects through MRI scans is also a critical part of the administration process.
Kisunla may cause side effects, some of which can be serious. The most common side effects are related to Amyloid-Related Imaging Abnormalities, or ARIA. These are changes in the brain seen on MRI scans, which can include temporary swelling (ARIA-E) or small spots of bleeding (ARIA-H). Most cases of ARIA are asymptomatic. Other common effects include infusion-related reactions like flushing or chills, headache, nausea, and falls. Your healthcare provider will monitor you for these effects, especially during the initial phase of treatment. It is important to discuss all potential risks with your doctor.
IsraelPharm offers a reliable and cost-effective way to access the medications you need. We are a trusted international online pharmacy connecting you with licensed pharmacy partners. Our team ensures that you receive genuine medications, like Kisunla, at competitive prices. We provide discreet and secure shipping, including required cold chain handling for sensitive products. With our dedicated customer service and commitment to quality, you can manage your treatment with confidence and convenience. Choosing IsraelPharm means prioritizing both your health and your budget without compromising on safety or service.
The most significant side effects associated with Kisunla are Amyloid-Related Imaging Abnormalities (ARIA). Other side effects may also occur.
Kisunla is indicated for the treatment of early symptomatic Alzheimer’s disease in adult patients who have been confirmed to have amyloid beta pathology. This includes patients with:
Kisunla is administered as an intravenous (IV) infusion in a clinical setting by a healthcare professional. The infusion is given once every four weeks to ensure a consistent level of the medication in the body. Each session lasts approximately one hour, during which you will be monitored for any immediate reactions. This method allows the antibody therapy to be delivered directly into the bloodstream for distribution to the brain.
Kisunla can cause Amyloid-Related Imaging Abnormalities (ARIA), which are changes detected on brain MRIs. ARIA-E involves temporary brain swelling, while ARIA-H involves small spots of bleeding. While these sound alarming, most cases do not have symptoms. When symptoms do occur, they may include headache, confusion, dizziness, or vision changes. Your doctor will monitor for ARIA with regular MRI scans before and during your treatment course.
Kisunla infusions are typically scheduled once every four weeks, or monthly. This regular dosing schedule is designed to maintain the drug's effectiveness in clearing amyloid plaques from the brain. The total duration of your treatment may vary. Your neurologist will use brain imaging to assess plaque levels and may decide to pause or stop treatment if a significant reduction is achieved. Regular follow-ups are essential.
Kisunla is not a cure for Alzheimer's disease. Currently, there is no cure for this condition. The goal of Kisunla is to slow the progression of the disease in its early stages. By removing amyloid plaques from the brain, it can help preserve cognitive function and daily abilities for a longer period. It is a treatment that modifies the underlying disease process rather than just managing symptoms.
Kisunla begins working to clear amyloid plaques from the very first dose. However, the clinical benefits, such as a slowing of cognitive decline, may not be noticeable for several months. The effectiveness is measured over time by comparing the rate of decline in treated patients to those who are not. Consistent monthly treatment is key to achieving the maximum potential benefit from the therapy. Your doctor will track your progress.
Before starting Kisunla, you must undergo testing to confirm the presence of amyloid beta plaques in your brain. This is typically done with a positron emission tomography (PET) scan or by analyzing a sample of cerebrospinal fluid (CSF). You will also need baseline magnetic resonance imaging (MRI) scans of your brain to check for any pre-existing conditions that could increase risks. These tests ensure the treatment is appropriate for you.
If you miss a scheduled infusion of Kisunla, you should contact your healthcare provider as soon as possible to reschedule. It is important to get your next dose as close to the original date as you can to maintain the medication's effectiveness. Do not wait for the next regularly scheduled appointment. Your doctor's office will provide guidance on the best way to get your treatment schedule back on track.
Kisunla may be used in combination with other symptomatic treatments for Alzheimer's, such as cholinesterase inhibitors (e.g., donepezil) or memantine. These medications work differently from Kisunla and may provide additional symptom management. Always inform your doctor about all medications you are taking, including over-the-counter drugs and supplements, to avoid any potential interactions. Your doctor will determine the best overall treatment plan for you.
Kisunla can cause infusion-related reactions, which typically occur during or shortly after the infusion. Symptoms can include changes in blood pressure, flushing, chills, fever, shortness of breath, or a rash. Your healthcare team will monitor you closely during each infusion. If you experience any of these symptoms, even after you have left the clinic, it is important to notify your doctor right away for guidance.
Kisunla's effectiveness can vary from person to person. Clinical trials have shown that it can slow cognitive and functional decline for many patients with early-stage Alzheimer's disease, but it does not work for everyone. Factors such as the stage of your disease and your individual biology can influence the response. Your neurologist will monitor your progress to evaluate how well the treatment is working for you over time.
Yes, Kisunla treatment requires diligent monitoring by your healthcare team. You will need routine Magnetic Resonance Imaging (MRI) scans before you start and at several points during therapy. These scans are crucial for detecting potential side effects like ARIA (Amyloid-Related Imaging Abnormalities) early. This monitoring helps ensure the treatment is administered safely and allows your doctor to make any necessary adjustments to your care plan.
Kisunla must be stored at refrigerated temperatures, between 2°C to 8°C (36°F to 46°F), in its original carton to protect it from light. It must not be frozen or shaken. Because it is administered in a clinic, your healthcare provider will handle the storage. For mail-order pharmacies like IsraelPharm, we use specialized cold chain shipping to ensure the medication arrives safely and maintains its integrity and effectiveness until it reaches your provider.
Send Your Prescription
No Hidden Fees
Generally 7-10 Business Days
IsraelPharm has been delivering lost cost prescriptions from Israel for over 15 years worldwide. Daily flights allow us to get your medications dispatched fast! Delivery to the USA is under 10 days and you can track and trace every order.
Learn how biologic medications like Stelara and Prolia treat chronic conditions by targeting specific parts of the immune system and bone cells.
For so many women, their own health takes a back seat – not because they ignore it, but rather because life is loud. Work, family, caregiving, aging parents, hormones, sleep, stress. Life is like a
Despite years of research and real-world use, there is still no FDA-approved testosterone therapy designed specifically for women. Now, that gap is getting renewed attention. Discussion around testosterone therapy for women has shifted in recent
